|
GR
|
Glucocorticoid receptor maturation in A431, A549 cells or serotonin pathways in mice
|
Mutations, trichostatin A (TSA) (1 μM), Tubacin (10 μM), ACY-738(2.5 μM) knock out or transgenesis
|
Espallergues et al. (2012); Hu et al. (2019); Jochems et al. (2015); Kovacs et al. (2005a, b); Lee et al. (2012); Murphy et al. (2005); Zhu et al. (2020)
|
|
ERα
|
Hippo pathway in ERα + or tamoxifen-resistant breast cancer
|
Tubacin (1 μM), Panobinostat (LBH589) (100 nM) or Dacinostat (LAQ824) (250 nM)
|
Fiskus et al. (2007); Yu et al. (2017)
|
|
HIF-1α
|
Glioblastoma growth and angiogenesis
|
LBH589 (40 nM) or TSA (500 nM)
|
Schoepflin et al. (2016); Yao et al. (2017); Zhang et al. (2010)
|
|
EGFR
|
Esophageal squamous cell carcinoma proliferation and migration
|
siRNA or Tubastatin (1 μM)
|
Tao et al. (2018); Kim et al. (2009); Gravina et al. (2013)
|
|
Kit
|
Growth inhibition, cell cycle arrest, apoptosis against malignant mast cell lines
|
AR-42 (3 μM)
|
Lin et al. (2010)
|
|
Her-2
|
Her-2 stability via the proteasome pathway in SK-BR-3 cells
|
Carbamazepine (CBZ) (100 μM) or TSA) (100 nM)
|
Kim et al. (2009); Gravina et al. (2013); Meng et al. (2011)
|
|
VEGFRs
|
Proteasomal degradation of vascular endothelial growth factor receptors
|
Suberoylanilide hydroxamic acid (SAHA) (1 μM), LAQ824 (300 nM) or TSA (30 nM) or Tubacin (100 nM)
|
Park et al. (2008); Verheyen et al. (2012)
|
|
AR
|
Proteasome degradation of AR in LNCaP cells or prostate cancer
|
siRNA, overexpression, genistein (25 μM), 4-HBAs (4-hydroxybenzoic acids) (50 μM), SAHA (10 μM), Sulforaphane (20 μM), Belinostat (PXD101) (0.5 μM) or 2‐75 (2.5 µM)
|
Hu et al. (2019); Gravina et al. (2013); Ai et al. (2009); Basak et al. (2008); Gibbs et al. (2009); Rosati et al. (2016); Seidel et al. (2016)
|
|
AhR
|
Aryl hydrocarbon receptor signaling in human aerodigestive epithelial cells
|
TSA (500 nM), SAHA (20 μM) or Tubacin (20 μM)
|
Kekatpure et al. (2009)
|
|
Rac1
|
Membrane ruffle formation and cell migration in MEFs
|
knock-out HDAC6
|
Gao et al. (2007)
|
|
Survivin
|
Autophagy and viability reduction in breast cancer cells
|
SAHA (1.4 μM)
|
Lee et al. (2016)
|
|
Bcr-Abl
|
Degradation of Bcr-Abl in human leukemia cells or FDCP-1 cells
|
LAQ824(100 nM), SAHA (5 μM), MRLB-223(10 μM) or siRNA
|
Rao et al. (2008); Bali et al. (2005); Lee et al. (2007); Newbold et al. (2013)
|
|
c-Raf
|
Degradation of c-Raf human in leukemia cells
|
Tubacin (3 µM) and siRNA
|
Rao et al. (2008)
|
|
tau
|
Degradation of tau in HEK293T or HeLa cells and tau pathology neurodegeneration in rTg4510 mouse models
|
Overexpression HDAC6, siRNA or tubastatin (25 mg/kg/day)
|
Selenica et al. (2014); Cook et al. (2012)
|
|
aurora-A
|
Migration and metastatic activity in breast cancer
|
MPT0G211 (10 μM) or tubastatin A (10 μM)
|
Hsieh et al. (2019)
|
|
IKKα
|
Proliferation and apoptosis in human myeloma cell line and primary myeloma cells
|
As2O3(5 μM)
|
Qu et al. (2012)
|
|
MIF
|
MIF stability via the proteasome pathway in cancer cells
|
siRNA or SAHA (5 μM)
|
Schulz et al. (2012)
|
|
cyclin D1 and CDK4
|
G1 growth arrest in lung cancer cells
|
NBM-T-BBX-OS01 (10 μM) or overexpression
|
Pai et al. (2015)
|
|
mutant p53
|
Preferential cytotoxicity for mutp53 tumor
|
SAHA (5 μM), siRNA, or A452(2 μM)
|
Li et al. (2011); Ryu et al. (2017b)
|
|
MMP-9
|
Migration and invasion activities in lung cancer
|
Honokiol (10 μM)
|
Pai et al. (2020)
|
|
NS5(Japanese Encephalitis Virus)
|
Viral RNA Synthesis
|
Tubacin (10 μM) or TBSA (10 μM)
|
Lu et al. (2017)
|
